IPCALAB.NSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 5月 2024 @ 14:21):

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India...

Stats
本日の出来高	152 294
平均出来高	525 178
時価総額	328.18B
EPS	INR0 ( 2024-02-13 )
次の収益日	( INR5.60 ) 2024-05-27
Last Dividend	INR4.00 ( 2022-11-22 )
Next Dividend	INR0 ( N/A )
P/E	58.27
ATR14	INR1.655 (0.13%)

ボリューム相関

長: -0.02 (neutral)

短: -0.16 (neutral)

Signal:(74.896) Neutral

Ipca Laboratories Limited 相関

10 最も正の相関
ALLCARGO.NS	0.878
RAJVIR.NS	0.838
AJRINFRA.NS	0.808
KHAITANLTD.NS	0.801

10 最も負の相関
FOCUS.NS	-0.833
AGI.NS	-0.82
BANCOINDIA.NS	-0.816
KOVAI.NS	-0.812
MAYURUNIQ.NS	-0.81
MEGH.NS	-0.804
HILTON.NS	-0.804
FINCABLES.NS	-0.802
BECTORFOOD.NS	-0.802
SUPERHOUSE.NS	-0.802

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Ipca Laboratories Limited 相関 - 通貨/商品

-0.40
( neutral )

0.30
( neutral )

-0.15
( neutral )

0.44
( neutral )

0.42
( neutral )

0.67
( moderate )

Ipca Laboratories Limited 財務諸表

Annual	2022
収益:	INR62.44B
総利益:	INR39.38B (63.06 %)
EPS:	INR18.58

FY	2022
収益:	INR62.44B
総利益:	INR39.38B (63.06 %)
EPS:	INR18.58

FY	2022
収益:	INR57.66B
総利益:	INR36.60B (63.48 %)
EPS:	INR34.85

FY	2021
収益:	INR53.41B
総利益:	INR35.39B (66.27 %)
EPS:	INR45.01

Financial Reports:

No articles found.

Ipca Laboratories Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR4.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Ipca Laboratories Limited Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.59 - low (19.38%) | Divividend Growth Potential Score: 3.87 - Decrease likely (22.67%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.150	1999-11-24
Last Dividend	INR4.00	2022-11-22
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	40	--
Total Paid Out	INR32.15	--
Avg. Dividend % Per Year	0.20%	--
Score	2.1	--
Div. Sustainability Score	3.59
Div.Growth Potential Score	3.87
Div. Directional Score	3.73	--

Next Divdend (Est)
(2024-11-15)

INR0 Estimate 0.00 %

Dividend Stability

0.08 Very Bad

Dividend Score

2.10

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.500	0.14%
2019	INR1.500	0.37%
2020	INR6.50	1.14%
2021	INR4.00	0.37%
2022	INR4.00	0.37%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SATIA.NS	Dividend Junior	2023-09-22	Annually	6	0.35%
MAHINDCIE.NS	Dividend Junior	2023-06-02	Annually	3	0.66%
GNA.NS	Dividend Junior	2023-08-31	Annually	7	1.43%
ATFL.NS	Dividend Junior	2023-07-04	Annually	16	0.24%
TNPETRO.NS	Dividend Junior	2023-09-18	Sporadic	23	2.02%
PFIZER.NS	Dividend Junior	2023-08-11	Annually	22	0.82%
JAYBARMARU.NS	Dividend Junior	2023-09-08	Annually	23	1.48%
DCMSHRIRAM.NS	Dividend Junior	2023-07-18	Semi-Annually	23	1.23%
SIYSIL.NS	Dividend Junior	2023-07-24	Semi-Annually	18	1.37%
MEDICAMEQ.NS	Ex Dividend Junior	2023-09-20	Annually	3	0.02%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0785	1.500	8.43	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.126	1.500	9.71	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	7.15	1.000	8.46	8.46	[3 - 30]
operatingCashFlowPerShareTTM	25.91	2.00	1.364	2.73	[0 - 30]
freeCashFlowPerShareTTM	25.91	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.655	1.000	2.42	2.42	[0.2 - 0.8]
operatingProfitMarginTTM	0.127	1.000	9.47	9.47	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.59

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	60.08	1.000	4.03	0	[1 - 100]
returnOnEquityTTM	0.126	2.50	9.81	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	25.91	2.00	1.364	10.00	[0 - 30]
dividendYielPercentageTTM	0.150	1.500	6.26	0	[0 - 0.4]
operatingCashFlowPerShareTTM	25.91	2.00	1.364	2.73	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	12.35	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0915	1.000	-0.213	0	[0.1 - 0.5]
Total Score				3.87

Ipca Laboratories Limited

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.